Microbiome Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Microbiome Therapeutics Market by Product Type (Probiotics, Prebiotics, Synbiotics (Combination of Prebiotics and Probiotics)), By Disease Indication (Digestive related disorders (Crohn’s disease, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Others)), Metabolic Disorders (Obesity, Diabetes, Others), Respiratory Infections, Cancer, Immune System, Oral Diseases, Skin Infections and Others and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global microbiome therapeutics market size valued USD 262.3 million in 2020 and expected to grow at a CAGR of 22.6% during the forecast period 2021-2027. A microbiome is genetic material of all microbes such as bacteria, virus, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant about oral health. Microbiome Therapeutics Market plays a significant role in human health and disease conditions. Global Microbiome Therapeutics Market is still nascent stage, very products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in the microbiome therapeutics market in terms of product launches, research and development activities. However, bigger players in the microbiome therapeutics market are focused to provide funding, collaborating and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series-B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.

Microbiome Therapeutics Market

MARKET SUMMARY
-
22.6% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 22.6%
  • Largest Market– Europe
  • Fastest Growing Market– North America

Microbiome Therapeutics Market

  • The report on global microbiome therapeutics market gives historical, current and future market sizes (US$ Mn) based on devices, application, end users and geographical regions.
  • microbiome therapeutics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Pfizer Inc.,
  • AB biotics,
  • Enterome,
  • Eligo Bioscience,
  • 4D Pharma plc,
  • Synlogic,
  • TargEDys.
Microbiome Therapeutics Market

Drivers And Restraints

Increase in evidence about the direct relationship of the microbiome in treating lifestyle diseases, autoimmune diseases such as Crohn’s, inflammatory bowel disease (IBS) conditions are fuelling the growth of the market. Currently, very few drugs are available in the market to treat these disease conditions. Furthermore, microbiome therapeutics are safer than conventional treatments as they are already present in the human body. Microbiome therapeutics didn’t possess any side-effects, unlike conventional drugs these factors will have a positive impact on the growth of the market. However, the lack of substantial clinical evidence about the microbiome benefits on human health and regulatory barriers might hamper the growth of the market over the forecast period.


Europe got significant share

Microbiome Therapeutics Market

Geographically market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe accounted for the larger share in terms of research and development followed by North America. Active involvement of government organisation owing to encourage the research on microbiome in European countries. For instance, MetaGenoPolis (MGP) program that was financed by French Initiative “Investissements d’Avenir” to understand the human microbiome impact on human health. In June 2014, MyNewGut project received funding from the European Union, to develop dietary interventions that have the impact on controlling obesity, diabetes, and cardiovascular disease conditions. In Asia-Pacific region, research on microbiome therapeutics is also actively carried out by research institutes through government funding programs. In 2010, Korean Microbiome Diversity Using Korean Twin Cohort Project was funded by National Research Foundation of Korea. The aim of the project is to identify target microbiome and genes that are associated with human diseases.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In July 2016, Series Therapeutics started a clinical trial on its synthetically designed microbiome drug SER-262, to treat Clostridium difficile infection conditions. The study is currently enrolling patients from 22 locations in the U.S.
  • In February 2015, 4D Pharma plc, U.K. based company, acquired Tucana that involved in development of microbiome therapeutics product to treat Irritable Bowel Syndrome (IBS) conditions
  • In January 2016, Takeda Pharmaceuticals Ltd and Enterome entered strategic drug discovery collaboration to conduct research and development on novel therapeutics that targets microbiome that plays crucial roles in multiple gastrointestinal disease conditions

Key

Report Outline

Microbiome Therapeutics Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Johnson & Johnson
  • Pfizer Inc.
  • AB biotics
  • Enterome
  • Seres Therapeutics
  • Vedanta Biosciences
  • Eligo Bioscience
  • 4D Pharma plc
  • Synlogic
  • TargEDys
  • Second Genome
  • LNC research & development
  • Takeda Pharmaceutical Company Ltd
  • PROBI
  • Ritter Pharmaceuticals.

Description

The global microbiome therapeutics market size valued USD 262.3 million in 2020 and expected to grow at a CAGR of 22.6% during the forecast period 2021-2027. A microbiome is genetic material of all microbes such as bacteria, virus, fungi, and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third bacteria in the gut are Bacteroides species, whereas Streptococcus species are dominant about oral health. Microbiome Therapeutics Market plays a significant role in human health and disease conditions. Global Microbiome Therapeutics Market is still nascent stage, very products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in the microbiome therapeutics market in terms of product launches, research and development activities. However, bigger players in the microbiome therapeutics market are focused to provide funding, collaborating and acquiring smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging research activities. The launch of microbiome therapeutics products in the market expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, the company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct the clinical investigation on SGM-109, a small molecule inhibitor of a microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series-B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX